Inhaled Flecainide Composition for Rapid Arrhythmia Conversion

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for cardiac arrhythmias, such as atrial fibrillation and paroxysmal supraventricular tachycardia, are inadequate due to high side-effect profiles, require extensive monitoring, and often necessitate high oral and intravenous doses leading to adverse cardiac events, making them costly and risky.

Innovation Solution

A pharmaceutical composition comprising a high concentration of flecainide salt in a liquid solution, formulated with cyclodextrin and an acid, administered via inhalation using a nebulizer to achieve rapid and effective cardioversion with minimal side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high oral and intravenous doses are used to compensate for absorption, metabolism, and dilution, then therapeutic effectiveness is achieved, but adverse cardiac events like pro-arrhythmias, QT prolongation, and torsade de pointes occur

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidadverse cardiac events

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces an intermediary substance (cyclodextrin inclusion complex) that facilitates drug delivery to the heart while preventing systemic distribution. This mediator approach allows the antiarrhythmic drug to reach the target tissue at effective concentrations without causing harmful effects through high blood concentrations, thereby resolving the contradiction between therapeutic effectiveness and adverse cardiac events.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention implements local quality by directing the drug specifically to the heart tissue through the cyclodextrin complex mechanism. The drug is concentrated at the target site (heart) rather than being distributed systemically, achieving effective treatment of arrhythmia while avoiding the harmful effects associated with high blood concentrations throughout the body.

Inventive Principle:

Principle #3Local quality

2Speed

If intravenous adenosine is used for cardioversion, then rapid conversion to normal sinus rhythm is achieved, but coronary vasoconstriction and adverse effects occur in patients with coronary artery disease

Engineering Contradiction:

Improveconversion speedVSAvoidcoronary vasoconstriction

Core Design Contradiction:

SpeedVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by delivering the antiarrhythmic drug directly to the heart tissue through cyclodextrin inclusion complexes. This localized delivery mechanism achieves rapid cardioversion effectiveness while avoiding the harmful coronary vasoconstriction caused by systemic intravenous adenosine, particularly in patients with pre-existing coronary artery disease.

Inventive Principle:

Principle #3Local quality

3Reliability

If ablation techniques are used to treat arrhythmias, then cardioversion is achieved, but high expense and potential need for multiple procedures occur

Engineering Contradiction:

Improvecardioversion successVSAvoidtreatment cost

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent represents a cost-effective, disposable pharmaceutical approach compared to expensive ablation procedures. The cyclodextrin inclusion complex formulation provides a single-use, affordable treatment option that achieves cardioversion without requiring costly invasive procedures or multiple sessions, making it accessible to a broader patient population.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

4Duration of action of stationary object

If oral medications are used for arrhythmia treatment, then maintenance therapy is provided, but long onset time and high doses are required

Engineering Contradiction:

Improvemaintenance therapy durationVSAvoidonset time

Core Design Contradiction:

Duration of action of stationary objectVSLoss of time

Solution Approach 1:

The patent applies parameter changes by altering the delivery route and formulation parameters. Instead of oral administration with slow absorption, the cyclodextrin inclusion complex enables rapid intratracheal or intravenous delivery, dramatically reducing onset time while maintaining effective concentrations for sustained arrhythmia treatment.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition allows for rapid conversion to normal sinus rhythm with minimal adverse effects, reducing the need for hospital visits and invasive procedures, and providing a safer, more cost-effective treatment option.

Implementation Method 1

The presence of cyclodextrin increases the solubility of the salt of flecainide as compared to a corresponding formulation without the cyclodextrin

Methodology Applied

Scientific EffectInclusion complex formation:

Implementation Method 2

administered via inhalation using a nebulizer

Methodology Applied

Scientific EffectAerosolization: Aerosol

Data Source

PatentUS12576073B2Antiarrhythmic formulation

Publication Date: 2026.03.17 INCARDA THERAPEUTICS INC

AI summary

Pharmaceutical compositions comprising an antiarrhythmic agent for treatment of a heart condition via inhalation. Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also disclosed.